← Back to Search

PS-PrEP for Preventing HIV Transmission (PS-PrEP Trial)

N/A

Waitlist Available

Research Sponsored by University of Chicago

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Eligible for PrEP according to the package insert

18 - 35 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up one year

Awards & highlights

PS-PrEP Trial Summary

This trial is testing whether a new intervention called Partner Services Pre-exposure Prophylaxis (PS-PrEP) is more effective than phone-based Pre-exposure Prophylaxis (PrEP) in getting people linked to care. The study will enroll high-risk individuals 18-35 years from clinic-based recruitment and referrals from social network based projects.

Who is the study for?

This trial is for English-speaking, African American/Black identified MSM aged 18-35 who live in the Chicago area more than half the year. Participants must own a personal cell phone, be HIV negative with completed counseling, and eligible for PrEP treatments according to guidelines but haven't taken PrEP in the last year.Check my eligibility

What is being tested?

The study compares two methods of linking high-risk individuals to Pre-exposure Prophylaxis (PrEP) care: a new PS-PrEP intervention group versus a control group using phone-based support (PrEPLine). The goal is to see which method is better at connecting people to care within three months after starting.See study design

What are the potential side effects?

While specific side effects are not detailed here, generally PrEP can cause symptoms like stomach pain, headache, weight loss and sometimes more serious effects on bone health or kidney function. Side effects vary from person to person.

PS-PrEP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I meet the criteria for taking PrEP as per its guidelines.

Select...

I am between 18 and 35 years old.

PS-PrEP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ one year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~one year

This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Surveying the uptake of PrEP care after randomized behavioral intervention or routine linkage

Timing of linkage to care after behavioral intervention

PS-PrEP Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: PS-PrEP Intervention GroupExperimental Treatment1 Intervention

Group II: CDPH Prevention ProjectsActive Control1 Intervention

Group III: PrEPLine Control GroupActive Control1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of ChicagoLead Sponsor

1,002 Previous Clinical Trials

817,686 Total Patients Enrolled

Media Library

PrEPLine Control Group Clinical Trial Eligibility Overview. Trial Name: NCT02749955 — N/A

HIV Transmission Research Study Groups: CDPH Prevention Projects, PS-PrEP Intervention Group, PrEPLine Control Group

HIV Transmission Clinical Trial 2023: PrEPLine Control Group Highlights & Side Effects. Trial Name: NCT02749955 — N/A

PrEPLine Control Group 2023 Treatment Timeline for Medical Study. Trial Name: NCT02749955 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any current opportunities for involvement in this experiment?

"Clinicaltrials.gov states that this trial, which was created on November 1st 2015 and last updated on October 28th 2022 is no longer recruiting patients. Thankfully, there are still multiple studies actively searching for participants to join their experiments."

Answered by AI

Could I qualify to participate in this medical trial?

"This medical research requires that those wishing to participate meet three criteria: they must demonstrate HIV transmission, exhibit the Transtheoretical Model of Change and be between 18-35 years old. Currently, 164 volunteers are needed for this study."

Answered by AI